Exploring the Success of Dxd ADC Platform in Optimizing Clinical Efficacy Through Plasma-Stable Linker-Payload Technology & Optimized DAR

• Analyzing the design innovations of the DXd ADC platform, specifically the plasma-stable linker-payload to understand its role in enhancing tumor selectivity
• Discussing translational and clinical outcomes of this platform in achieving efficacy in multiple tumor types
• Demonstrating bystander antitumor effect and its enhanced ability in tumor killing

Speakers:

Gerold Meinhardt

Vice President, Head Global Team Leads, Early Oncology

Daiichi Sankyo